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Aim: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia 
(AML) and in healthy subjects using biochip array technology. Methods: A total of 15 AML patients and 15 healthy subjects (blood 
donors) were studied. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. This 
approach allows multi-analytical determination from a single sample. T-tests were used for statistical analysis. Results: In newly 
diagnosed AML patients, we found significant increase (p < 0.01) in serum VCAM-1, ICAM-1, E-selectin, L-selectin, and sig-
nificant increase (p < 0.05) in serum IL-6, IL-8. No significant differences were found in the levels of other evaluated cytokines 
and adhesion molecules. Conclusion: Our results indicate that serum levels of specific cytokines and adhesion molecules  ( VCAM-1, 
ICAM-1, E-selectin, L-selectin, IL-6, IL-8) are significantly altered in patients with newly diagnosed AML, showing activity 
of the disease. Whether these alterations could serve as a prognostic marker for AML is not known. Further studies will be needed 
to define the potential role of these and additional markers in the risk stratification of AML.
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Cytokines and adhesion molecules have been 
studi ed in many pathological states including cancer 
[1–3] and acute leukemias [4, 5]. Alterations in this 
interacting functional network may have direct effect 
on the malignant cells or have indirect effect on leuke-
mogenesis through altered functions of bone marrow 
stromal elements [6, 7]. The knowledge gained from 
multiple cytokine and adhesion molecule analysis 
could allow better diagnosis and disease manage-
ment, since cytokines or their receptors may also 
represent a target for specific anticancer therapy 
at the molecular level. Recently, some studies reported 
the possible diagnostic and prognostic use of cytokine 
levels in newly diagnosed acute myeloid leukemia 
(AML) and myelodysplastic syndromes [8–10].
The aim of our pilot study was to evaluate serum 
levels of multiple cytokines and adhesion molecules 
in patients with newly diagnosed AML and in healthy 
subjects using the innovative biochip array technology.
Serum samples of 15 newly diagnosed de novo 
AML patients (median age 51, range 24–61 years, 
8 males) and 15 healthy subjects (median age 41, 
range 25–58 years, 11 males) were analyzed. The study 
was approved by the local Ethics Committee and all 
patients gave a written consent.
We evaluated serum levels of the following 17 cyto-
kines and 5 adhesion molecules: interleukins (IL-1 alpha, 
IL-1 beta, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,  IL-12p70, 
IL-13, IL-23), vascular endothelial growth factor (VEGF), 
tumor necrosis factor-alpha (TNF-alpha), interferon-
gamma (IFN-gamma), epidermal growth factor 
(EGF), monocyte chemotactic protein-1 (MCP-1), 
 E-selectin, L-selectin, P-selectin, intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion mole-
cule-1 (VCAM-1). All analytes were measured by biochip 
array technology using chemiluminescent sandwich 
immunoassays applied to the Evidence Investigator 
analyzer (Randox Laboratories Ltd., Crumlin, UK).
Statistical analysis was performed with the “Statis-
tica” program. T-tests were used. The values were ex-
pressed as mean ± SD. Probability values p < 0.05 were 
considered statistically significant.
Comparing serum cytokine and adhesion mo-
lecule levels in AML patients and in healthy subjects, 
we found significant increase in AML patients in serum 
VCAM-1 (716.22 ± 364.38 mcg/L  vs  328.31  88.66  mcg/L; 
p < 0.01), ICAM-1 (659.61 ± 259.50 mcg/L vs 196.69  
36.06 mcg/L; p < 0.01),  E-selectin (30.19 ± 20.46 mcg/L 
vs 13.89  4.80 mcg/L; p < 0.01), L-selectin (2179.35 ± 
1169.39 mcg/L vs 1104.54  243.45 mcg/L; p < 0.01), 
IL-6 (46.24 ± 83.14 ng/L  vs 0.52  0.44 ng/L; p < 0.05), 
IL-8 (104.99 ± 167.30 ng/L vs 4.87  3.09 ng/L; 
p < 0.05). Serum levels of other evaluated cytokines 
and adhesion mo lecules were without significant dif-
ferences.
Altered levels of cytokines and adhesion molecules 
have been found in many pathological states and have 
been linked to many diseases including  cardiovascular 
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diseases and cancer [1–3, 11–13]. The cytokine 
system constitutes an interacting functional network 
where the contribution from single cytokines is modu-
lated by the levels of other cytokines. It may therefore 
be more relevant to look at the total serum profile 
of these mole cules.
Biochip array technology enables simultaneous 
detection of multiple cytokines and adhesion molecules 
in a single sample and provides valuable information re-
lating to each tested analyte and possible associations 
between analytes in each sample [14, 15]. We recently 
published our experience with biochip arrays for cyto-
kines and adhesion molecules in acute lymphoblastic 
leukemia patients [16]. The presented paper is among 
the first published studies using the innovative biochip 
array technology to determine circulating levels of cy-
tokines and adhesion molecules in AML patients.
Our results indicate that serum levels of specific 
cytokines and adhesion molecules (VCAM-1,  ICAM-1, 
E-selectin, L-selectin, IL-6, IL-8) are significantly al-
tered in patients with newly diagnosed AML, showing 
activity of the disease. Whether these alterations could 
serve as a prognostic marker for AML is not known. 
Further studies in a larger number of patients and 
comparing cytokine and adhesion molecule levels 
with established prognostic markers (cytogenetics, 
molecular genetics) will be needed to define the po-
tential role of these and additional markers in the risk 
stratification of AML patients.
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